Overview
TLX market data
Price History
TLX price chart · 1M
- O
- 11.28
- H
- 11.35
- L
- 11.28
- C
- 11.35
- Vol
- 3,752.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $11.28
- Previous Close
- $11.12
- Day High
- $11.35
- Day Low
- $11.28
- 52 Week High
- $12.46
- 52 Week Low
- $8.70
- 7 Day Return
- -8.62%
- 30 Day Return
- +11.33%
- 90 Day Return
- +20.31%
- 1 Year Return
- +8.72%
- Daily Notional Volume
- $42.6K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- — Diluted earnings per share over the trailing twelve months.
- Beta
- — Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $6.28 – $12.60 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap —.
Company News
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price TargetBenzinga · Aug 20, 2026, 4:47 PM
Reported Earlier, Telix Pharmaceuticals Guides FY 2026 Revenue Of $950M-$970M, Total Income Above $1B, Reaffirms R&D Guidance Of $230M-$270MBenzinga · Aug 20, 2026, 11:25 AM
Reported Earlier, Telix Pharmaceuticals Reports H1 2026 Revenue Of $477M, Up 22% YoY, And Profit After Tax Of $38M Versus $2M LossBenzinga · Aug 20, 2026, 11:25 AM
Telix H1 2026 Results: Investor Webcast NotificationGlobenewswire Inc · Jul 30, 2026, 11:15 PM
TLX591-Tx ProstACT SELECT Study Published in Cancers JournalGlobenewswire Inc · Jul 21, 2026, 10:00 PM
Telix Pharmaceuticals Announces Publication Of Results From The ProstACT SELECT Study In Cancers, A Peer-Reviewed Journal; Peer-Reviewed Publication of ProstACT SELECT1 Results Confirm The Utility Of 68Ga -PSMA-PET Imaging To Select Patients For TLX591-Tx Therapy Using A Theranostic ApproachBenzinga · Jul 21, 2026, 9:03 PM
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline ProgressGlobenewswire Inc · Jul 21, 2026, 11:00 AM
Reported Earlier, Telix FY2026 Revenue Guidance $950M-$970M Plus $40M Regeneron Payment, Total Expected Above $1BBenzinga · Jul 21, 2026, 6:43 AM
Reported Earlier, Telix Q2 Revenue $247M Up From $204M, With Precision Medicine Up 30% YoYBenzinga · Jul 21, 2026, 6:42 AM
Telix Pharmaceuticals Announces That The First Patient Has Been Dosed With TLX250-Tx In The LUTEON StudyBenzinga · Jul 20, 2026, 9:14 PM